Equillium has dosed the first subject in its Phase 1 clinical trial of EQ504, an oral drug targeting inflammatory diseases like ulcerative colitis. The randomized, placebo-controlled study in Australia will assess safety, tolerability, and drug activity, with topline data expected by Q2 2027. Concurrently, Equillium secured $20 million in additional funding, extending its cash runway to 2029. Positive Phase 1 results could lead to a proof-of-concept study in ulcerative colitis patients later in 2027.
Equillium's Phase 1 clinical trial dosing news is current as of Oct 26, 2026 19:02 WIB. For readers following health-sector stocks, here is Pluang's market snapshot as of that time: out of 150 priced US health-sector stocks, 78 rose and 48 fell. Notable movers include AbCellera Biologics Inc (ABCL) at USD 12.00 with a 1-day change of +1.52% and a typical hold time of 41 days, DENTSPLY SIRONA Inc (XRAY) at USD 9.57 with a 1-day change of +1.48%, and Iovance Biotherapeutics Inc (IOVA) at USD 14.29 with a 1-day change of +1.42%.
Smithfield Foods has created a $250,000 Future Leaders Scholarship program at Christopher Newport University to support eight incoming business students with $7,500 annual scholarships renewable for up to four years. The program aims to help local st...
E-Power Inc.'s joint venture, Sunrise Guizhou, received RMB 110 million of a planned RMB 200 million capital increase, raising its registered capital and valuing the company at RMB 2 billion post-money. The funds will support business expansion, R&D,...
AS Tallinna Sadam has signed a €50 million unsecured loan agreement with Swedbank, with a 5-year term and interest based on 3-month Euribor plus a margin. The loan will be fully drawn on October 26, 2026, and matures on October 26, 2031. This financi...
AS Tallinna Sadam signed a €50 million unsecured loan agreement with AS Swedbank, maturing in five years with an interest rate based on 3-month Euribor plus margin. The loan, drawn on October 26, 2026, will be used to redeem bonds worth €50.4 million...
Vita Coco, a leading coconut water brand, has partnered with Homesick to create a limited-edition candle collection inspired by Vita Coco Treats flavors: Strawberries & Creme and Frosted Lemonade. The candles capture the essence of these flavors thro...
